Venus Remedies Ltd. has received Good Manufacturing Practices (GMP) certification from Ukraine for Meropenem 500mg, Meropenein 1000mg, Meropenem 2000mg, Oxaliplatin 5mg/mL, Paclitaxil6mg/ml,Cisplatinlmg/ml, Imipenem/Cilastatin500mg/500mg of its Carl)apenem & Oncology production facilities in Baddi to pave the way for GMP certificatious from European Medicines Ageney and other Pharmaceutical Inspection Convention/Cooperation Scheme Q'Icrs) monber nations. With Ukraine extending GMP to au seven facilities of Venus Remedies in Baddi, the company is looking to expand its product portfoho in other EU markets as well. In a far-reaching validation of its worldrolass manufacturing standards, has received Good Manufacturing Practices (GMP) certification from Ukraine forMeropenem 500mg, MerOPenein 1000mg, Meropenein 1mg, Meropenein 100mg, Oxaliplatin5mg/ml, Paclitaxil 6mg/ml, Cisplatinlmg/ml, Imipenem/Cilastatin500mg/500mg of its Carbapenem& Oncology produetion facilities at its unit in Baddi, Himachal Pradesh.

Granted by the State Service of Ukraine on Medicine and Dug Control (SMDC) after a stringent and elaborate audit, this certification is expected to pave the way for GM PIC/S recognition for GMP certificatious for Venus Remedies from European Medicines Agency and many medicines regulatory authorities of European Union@U) member states and othercountriesspread across the globe which follow the Pharmaceutical Inspection Convention/Cooperation scheme C/Icrs). This international GMP approval, the 27th for Venus Remedies, will also enable the company to expand its product portfolio globally with more marketing authorisatious not only from Ukraine, which happens to be one of the pharmaceutical markets in the Common wealth of Independent States (CIS) with a worth of USD 5 billion, but other global markets as well. Notably, India is the second exporter of pharma products to Ukraine after Germany.

Plc/S includes 54 countries, which together represent a USD 222 billion market, and Venus Remedies is already present in 04 PIcrs member states. The company also has a presence in 16 countries in the EU, which has a market size of USD 350 billion. Reinforcing the position of Venus Remedies as a global leader in the pharmaceutical industry, the approval covers the company's non-cephalosporin (calbapenem) and oncology parenteral facilities, comprising liquid and lyophilised injections, ampoules, liquid vials, general lyophilised vials, prefilled syringes and intravenous fluids.